Percutaneous rotational coronary atherectomy (PRCA) is commonly used in the percutaneous treatment of diffuse, calcified coronary lesions in stable coronary syndromes (SCSs) and facilitates successful delivery and deployment of balloons and stents. Early experience with PRCA cautioned its use in acute coronary syndromes (ACSs). However, the evolution of the PRCA technique and improved antiplatelet pharmacotherapy has broadened its use in ACSs also. A total of 1,112 consecutive patients with an ACS (n ‫؍‬ 269) or SCS (n ‫؍‬ 843) who underwent PRCA of 1,483 lesions were examined retrospectively to evaluate the angiographic and short-term clinical outcomes. Troponin-I was elevated in 33.3% of the ACS group and in 0.6% of the SCS group at baseline (p <0.001). Angiographic complications occurred more frequently in the ACS group (18.6% vs 13.1%, p ‫؍‬ 0.02). There was no difference in major complications between the groups (ACS 1.1% vs SCS 0.8%; p ‫؍‬ 0.44). The incidence of any periprocedural creatinine kinase-MB elevation was 17.1% versus 18.9% (p ‫؍‬ NS) and 30-day major adverse cardiac events (death, disabling stroke, creatine kinase-MB >3 times the upper limit of normal, urgent revascularization) was 5.9% versus 4.6% (p ‫؍‬ NS) when comparing the ACS and SCS groups, respectively. With current techniques and antiplatelet therapy, PRCA can be safely performed in ACSs when lesion morphology dictates, with outcomes comparable to that achieved in SCSs. Although angiographic complications occurred more frequently in the ACS group, this did not result in a significantly higher incidence of postprocedural myonecrosis or 30-day major adverse cardiac events. ᮊ2003 by Excerpta Medica, Inc.
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(Am J Cardiol 2003;92:1404 -1408) P ercutaneous rotational coronary atherectomy (PRCA) using the Rotablator (Scimed, Boston Scientific Corp., Maple Grove, Minnesota) is used in the treatment of chronic diffuse, complex, heavily calcified lesions to facilitate successful delivery and expansion of balloons and stents. [1] [2] [3] [4] [5] [6] [7] [8] [9] Compared with stable coronary syndromes (SCSs), patients with acute coronary syndromes (ACSs) may have angiographic and angioscopic thrombus that can cause slow flow and other complications after PRCA. 10 Advances in pharmacologic therapies, [11] [12] [13] procedural equipment, and techniques 14 -17 may allow PRCA to be used for appropriate lesions in ACSs. In the present study we examined and compared the angiographic and shortterm clinical outcomes of PRCA in ACSs versus SCSs when lesion morphology dictated its use in a large consecutive series studied at a single center.
METHODS
Between July 1999 and February 2002, 1,112 consecutive patients who underwent PRCA (of a total of 5,760 patients [19%]) were identified from the Institutional Review Board-approved Interventional Database at the Mount Sinai Hospital, New York. The patients were divided into 2 groups: stable and acute coronary syndromes, according to the clinical presentation at the time of intervention. Patients in the ACS category qualified if they had pain at rest, crescendo angina, dynamic ST-or T-wave changes, or a recent (Ͻ2 weeks) acute myocardial infarction. After hospital discharge, patients were either seen in a clinic by a physician or contacted by telephone for 30-day follow-up, which was available in 1,098 patients.
Procedure: A total of 1,112 patients (with 1,483 lesions) underwent atherectomy with the Rotablator as previously described. 14 The decision to use PRCA was made by the operator and based on lesion morphology; 5 interventionalists performed PRCA during the study period, with 1 operator (SKS) performing 52% of the procedures. The usual indications were calcification in complex lesions, ostial lesions, bifurcation lesion, total occlusion, and diffuse disease. Consistent with standardized laboratory practice, individual burring runs were kept at 15 to 20 seconds with burr speeds of 140,000 to 150,000 rpm and targeted overall burr-to-artery ratio of 0.5 to 0.6. Excessive burr decelerations Ͼ5000 rpm from the platform speed were strictly avoided by gentle, gradual burr advancement in a "pecking" fashion. Rotaflush with normal saline containing a cocktail of nitroglycerine (5 mg/L), verapamil (5 mg/L), and heparin (5000 U/L) was continuously infused through the Teflon Rotablator sheath. 14, 17 Episodes of hypotension (systolic pressure Ͻ100 mm Hg) were treated with intravenous neosynephrine (0.1 mg boluses) and intraaortic balloon counterpulsation when sustained hypotension or clinical signs of pulmonary congestion were encountered.
Adjunctive medical therapy: All patients received aspirin 325 mg before the procedure or clopidogrel 300 mg in patients with aspirin intolerance. Aspirin was continued indefinitely after the procedure and, in cases of stent implantation, clopidogrel 75 mg daily was administered for 30 days after an initial loading dose of 300 mg. Unfractionated heparin was administered in boluses to achieve an activated clotting time of Ϸ250 seconds in the presence of a glycoprotein IIb/IIIa inhibitor and Ϸ300 seconds in the absence. Glycoprotein IIb/IIIa inhibitors were used at the discretion of the individual operator and were administered only after completion of rotational atherectomy in angulated, heavily calcified, and totally occluded lesions due to concern of perforation caused by the burr.
Angiographic analysis: Lesion diameter percent stenosis, lesion length, vessel diameter, and other lesion characteristics were assessed by 1 operator (SKS) using visual analysis and an automated computer edge detection program. The findings were prospectively entered into the interventional database.
Enzyme analysis: Creatinine kinase (CK)-MB isoenzyme was measured at 3 time points: immediately before and at 6 to 8 hours and 12 to 24 hours after intervention. The laboratory normal level for CK-MB is 16 U/L, and post-procedural CK-MB was banded into 3 groups: 1 to 3 times the upper limit of normal (16 to 48 U/L), 3 to 5 times the upper limit of normal (48.1 to 80 U/L), and Ͼ5 times the upper limit of normal (Ͼ80 U/L). CK-MB data were available in 100% of the group. Troponin-I was measured by standard laboratory techniques immediately before intervention in 940 patients (84.5%). A troponin-I level Ͼ2 ng/L was regarded as elevated.
Definitions: Angiographic success was defined as a Ͻ30% diameter obstruction at the end of the procedure. A major complication was defined as occurrence of death, emergency bypass surgery (surgery on the same day of intervention), Q-wave myocardial infarction, or peak CK-MB Ͼ8 times the upper limit of normal (Ͼ128 U/L). A major adverse cardiac event (MACE) at 30 days-the primary end point of the study-was defined as occurrence of either CK-MB 3 times the upper limit of normal, emergency bypass surgery, death, disabling stroke, or urgent target vessel revascularization. Angiographic complications were defined as vessel closure during percutaneous intervention (persistent or transient), residual dissection at the end of the procedure, the occurrence of slow flow (less than Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow in the absence of dissection or major distal embolization) at any time during intervention, distal embolization, dye extravasation, frank vessel perforation, and side branch closure of vessel size Ͼ1.5 mm.
Statistical analysis: The primary end point of the study was 30-day MACEs, whereas incidence of postprocedural CK-MB elevation and angiographic complications were secondary end points. Continuous data are expressed as mean Ϯ SD and were compared between the SCS and ACS groups by means of unpaired t or Mann-Whitney tests, as appropriate. Categoric data are expressed as percentages and were compared by chi-square tests.
Univariate analysis was done to identify factors significantly associated with an increased risk of angiographic complications and CK-MB release. Univariate factors with p value Ͻ0.1 were used in multiple regression analyses to identify independent factors. A p value of Ͻ0.05 was considered significant. All statistical analyses were performed using SPSS for Windows (SPSS Inc., Chicago, Illinois) and SPLUS software (Seattle, Washington).
RESULTS
Baseline clinical characteristics of the 1,112 patients (269 ACSs and 843 SCSs) are listed in Table 1 . Mean age of the population was 68 Ϯ 12 years in the ACS group and 66 Ϯ 11 years in the SCS group (p ϭ 0.015). Sixty patients (22.3%) in the ACS group had an acute myocardial infarction at a mean interval of 3.8 Ϯ 2 days (range 2 to 12) before rotablation. The ACS group contained more diabetics (46.5 vs 38.1%, p ϭ 0.015), more frequently had a prior (remote) myocardial infarction (34.9 vs 27.4%, p ϭ 0.018), and had a lower ejection fraction (51.2 Ϯ 11 vs 53.5 Ϯ 10, p ϭ 0.003). There were also trends toward more women, lower body mass index, a higher incidence of chronic renal insufficiency (serum creatinine Ն1.5 mg/dl), and multivessel coronary disease in the ACS group. Preprocedural troponin-I was elevated in 33.3% of patients in the ACS group and in 0.6% of patients in the SCS group (p Ͻ0.001). Angiographic characteristics of the 2 groups are listed in Table 2 . Most lesions in the 2 groups were de novo, with restenotic lesions comprising 17.1% in the ACS group and 20.2% in the SCS group (p ϭ 0.42). There were no significant differences in lesion characteristics. Procedural characteristics are listed in Table 3 . Maximum burr size and the number of burrs used were significantly greater in the stable group (1.67 Ϯ 0.2 vs 1.63 Ϯ 0.2, p ϭ 0.015 and 1.22 Ϯ 0.4 vs 1.16 Ϯ 0.4, p ϭ 0.035). Stents were deployed in 70.6% of ACS patients and in 72.5% of SCS patients (p ϭ NS). There were no other significant procedural differences, including the use of glycoprotein IIb/IIIa inhibitors (used in Ϸ90% of patients in both groups).
Angiographic complications are listed in Table 4 . Side branch closure occurred more frequently in the ACS group (4.5% vs 2%, p ϭ 0.029). There was also an insignificantly higher incidence of slow flow (4.1% vs 2.9%, p ϭ 0.31) and residual dissection (10.4% vs 7.5%, p ϭ 0.13) in the ACS versus the SCS group, respectively. Any angiographic complication occurred significantly more frequently in the ACS group (18.6% vs 13.0%, p ϭ 0.024). Hypotension requiring intra-aortic balloon counterpulsation was infrequent and not significantly different between groups (p ϭ NS). On multivariate logistic regression analysis, factors significantly associated with an increased risk of angiographic complications were multivessel disease (odds ratio 1.8, p ϭ 0.002), female sex (odds ratio 1.8, p ϭ 0.001), presentation with ACSs (odds ratio 1.5, p ϭ 0.024), previous myocardial infarction (odds ratio 1.5, p ϭ 0.06), and diabetes (odds ratio 1.4, p ϭ 0.05). An abnormal baseline troponin-I was significantly associated with angiographic complication during univariate but not multivariate analysis.
Peak postprocedural CK-MB was not significantly different between the ACS and SCS groups (12.58 Ϯ 17.6 vs 12.56 Ϯ 20.1 U/L; p ϭ 0.66). A small proportion of patients in each group (ACS 4.5% and SCS 3.4%; p ϭ 0.44) had a baseline CK-MB Ն16 U/L. In patients with normal baseline CK-MB, the incidence of any CK-MB elevations and individual subgroups was not significantly different between the 2 groups ( Figure 1 ). On multivariate logistic regression analysis, only burr duration was significantly associated with CK-MB release (odds ratio 1.6, p ϭ 0.004). Angiographic complications and lesion length showed trends toward a higher incidence of CK-MB release (odds ratio 1.4, p ϭ 0.16 and odds ratio 1.01, p ϭ 0.15, respectively). Troponin-I was not routinely measured after the procedure for a large portion of the study period; therefore, no meaningful analysis could be made of these data.
There was 1 case of in-hospital death in the SCS group (p ϭ NS), and major complications were not Values are expressed as mean Ϯ SD or n (%).
different between the ACS and SCS groups (1.1% vs 0.8%; p ϭ 0.67). In addition, emergency bypass surgery was not required in any patient. The incidence of urgent target vessel revascularization and disabling strokes was slightly higher in the ACS group (0.7% vs 0%, p Ͻ0.012 and 0.4% vs 0%, p ϭ 0.08, respectively); however, the absolute event rates were extremely low. The 30-day MACE rate was also similar between the ACS and SCS groups (5.9% vs 4.6%, p ϭ 0.38).
DISCUSSION
Although early studies of PRCA had cautioned its use in possible thrombus-containing lesions, 5 ,10 the present study shows that PRCA can be performed in appropriately selected lesions causing ACSs. Outcomes are comparable to those observed in SCSs, with optimal angiographic and clinical results.
Angiographic complications were seen more frequently in the ACS group, especially a significantly higher incidence of side branch closure and a trend toward more slow flow in the ACS group. Importantly, however, this did not translate into a higher incidence of periprocedural CK-MB elevation in the ACS group. Furthermore, no significant difference in CK-MB elevation, major complications, or 30-day MACE was observed between the ACS and SCS groups. Although burr size and numbers were higher in the SCS versus ACS group, they did not predict any CK-MB elevation in multivariate analysis; duration of ablation was the predictor during multivariate analysis and was not different between the 2 groups. The relative safety of PRCA in the present study is attributable to a number of advances in adjuvant pharmacotherapy [11] [12] [13] and rotablation techniques. 14 -17 Important advances in pharmacotherapies include standard use of thienopyridines after stenting and periprocedural use of glycoprotein IIb/IIIa inhibitors. Standard use of glycoprotein IIb/IIIa inhibitors has been shown to reduce ischemic complications and CK-MB increases after PRCA in a randomized study. 12 In vitro, pretreatment with abciximab in experimental models has also been observed to reduce platelet activation induced by burr speeds of 150,000 and 180,000 rpm. 13 The standard use of lower burr speeds (140,000 to 150,000 rpm) in our laboratory has also been a factor because lower speeds (140,000 vs 180,000 rpm) have been associated with significantly reduced platelet activation. 15 Shorter ablation times (15 to 20 seconds), slow and gradual burr advancement, and strict avoidance of sharp drops in burr speeds (Ͼ5000 rpm) have been associated with reduced heat generation in vitro, 16 lower restenosis rates, and periprocedural CK-MB elevation in clinical studies. 18 Severe spasm, a frequent occurrence in early experience with PRCA, has been virtually eliminated with the standard use of a vasodilator "cocktail" in the rota-flush and liberal use of intracoronary nitrate. 14, 17 An important factor in the success of rotablation in the ACS group was the time interval between recent myocardial infarction and PRCA. Approximately 22% of the ACS group had a recent (Ͻ2 weeks) myocardial infarction. Through experience we have found that very early rotablation after a myocardial infarction is associated with increased angiographic and ischemic complications; therefore, some of these patients Values are expressed as mean Ϯ SD or n (%). (Ϸ15%) with long and heavily calcified lesions were delayed for 4 to 5 days after diagnostic coronary angiography before proceeding with rotablation. Our study reported higher incidences of old age, prior MI, and diabetes and lower ejection fraction in ACS versus SCS groups, probably reflective of advanced calcific coronary lesions causing ACSs in elderly and diabetic persons. The routine use of smaller final burr-to-artery ratios (Ͻ0.7) is also believed to have been a significant factor in the low incidence of angiographic and ischemic complications seen in this study. Larger burr-toartery ratios (Ͼ0.7) and more aggressive debulking have been shown to increase periprocedural infarction and serious angiographic complications compared with use of smaller burr sizes (Ͻ0.7). 18 -20 In this setting, moderate debulking with a low burr-to-artery ratio (Ͻ0.6) is believed to improve lesion compliance by removing superficial calcium, thereby facilitating balloon and stent delivery and expansion. Therefore, rotablation can be safely performed in appropriate lesions, even in the setting of ACSs.
